Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities by Angela, Esposito et al.
  
 
 
This is an author version of the contribution published on: 
Questa è la versione dell’autore dell’opera: 
Cancer Treat Rev. 2014 Jun;40(5):648-55. doi: 10.1016/j.ctrv.2013.10.003. Epub 
2013 Oct 23. 
 
The definitive version is available at: 
La versione definitiva è disponibile alla URL: 
http://www.sciencedirect.com/science/article/pii/S0305737213002077 
  
Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research 
opportunities 
 
Angela Espositoa, Alberto Bardellib, c, d, Carmen Criscitielloa, Nicoletta Colomboe, Lucia Gelaoa, Luca 
Fumagallia, Ida Minchellaa, Marzia Locatellia, Aron Goldhirschf, Giuseppe Curiglianoa,*  
a Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Via Ripamonti 
435, 20133 Milano, Italy 
b Department of Oncology, University of Torino, Candiolo, Torino, Italy 
c IRCC Institute for Cancer Research and Treatment, Candiolo, Torino, Italy 
d FIRC Institute of Molecular Oncology (IFOM), Milano, Italy 
e Division of Gynecologic Oncology, Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy 
f Breast Cancer Program Istituto Europeo di Oncologia, Via Ripamonti 435, 20133 Milano, Italy 
 
Abstract 
Circulating cell-free DNA represents a non-invasive biomarker, as it can be isolated from human plasma, 
serum and other body fluids. Circulating tumor DNA shed from primary and metastatic cancers may allow 
the non-invasive analysis of the evolution of tumor genomes during treatment and disease progression 
through ‘liquid biopsies’. The serial monitoring of tumor genotypes, which are instable and prone to 
changes under selection pressure, is becoming increasingly possible. The “liquid biopsy” provide novel 
biological insights into the process of metastasis and may elucidate signaling pathways involved in cell 
invasiveness and metastatic competence. 
This review will focus on the clinical utility of circulating cell free DNA in main solid tumors, including 
genetic and epigenetic alterations that can be detected. 
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Introduction 
Improvement in the clinical outcome of many cancer types is likely to be achieved by giving patients a drug 
tailored to the genetic makeup of their tumor. The recent surge in high-throughput sequencing of cancer 
genomes is delivering more accurate tumor genome information, and it can be anticipated that more 
predictive biomarkers will be identified and that patients will increasingly be treated by focusing on the 
genetic architecture of their particular tumor rather than on the tumor’s location or histological features. 
Circulating cell-free DNA (cf-DNA) represents a non-invasive biomarker, as it can be isolated from human 
plasma, serum and other body fluids [1]. Cf-DNA offer a unique opportunity for serially monitoring tumor 
genomes in a non-invasive manner. As cf-DNAs is a potential surrogate for the tumor itself, it is often 
referred to as ‘liquid biopsy’. 
In 1940 Mandel and Métais observed, for the first time, the presence of cell-free nucleic acid in the blood 
of healthy individuals [2]. 
Thirty years later, Leon et al. reported elevated levels of cf-DNA in the circulation of cancer patients in 
comparison with healthy individuals [3] and the data were confirmed in several studies [4], [5] and [6]. 
Subsequently, several studies reported a variety of alterations in cf-DNA such as mutations in oncogenes 
and tumor suppressor genes [7], microsatellite variances [8], and promoter hypermethylation [9]. 
The levels of cf-DNA might also reflect physiological and pathological processes that are not tumor-specific. 
Increased levels may be found in patients with benign lesions, inflammatory diseases and tissue 
trauma [10], which makes it difficult to evaluate the extent to which cf-DNA in the circulation of a patient is 
cancer specific. 
Although the data on cf-DNA are extensive, the possible usefulness of this marker in the clinical setting 
remains controversial and, presently, the evaluation of cf-DNA is not yet approved in any clinical guideline. 
In our review we will focus on the findings on cf-DNA in breast, lung, colorectal, ovarian and prostate 
cancers and discuss its relevance and potential use as diagnostic and prognostic marker. 
Biology of circulating cell free DNA 
The source of cf-DNA is still uncertain. A proportion seems to derive from nucleated blood cells; wild-type 
DNA has been detected in the plasma of cancer patients as well as in that of healthy controls. In cancer 
patients a considerable proportion of plasma DNA originates from tumor cells [11]. The apoptosis and 
necrosis of cancer cells in the tumor microenvironment are the possible explanations for the release of the 
nucleic acids into the blood. 
Macrophages usually engulf necrotic and apoptotic cells and then they release the digested DNA into the 
tissue environment [11]. Another hypothesis is that cf-DNA is due to the lyses of circulating cancer cells or 
micro metastases shed by tumor [11]. It was also hypothesized that the tumor actively releases DNA into 
the bloodstream [11]. 
The amount of cf-DNA that derives from tumor cells changes owing to the size and the state of the tumor. 
The proportion of cf-DNA is also conditioned by clearance, degradation and other physiological filtering 
events of the blood and lymphatic circulation[12]. However the concentration of cf-DNA in serum of cancer 
patients is about 4 times that of healthy controls [13]. The size of the DNA released from dead cancer cells 
varies between small fragments of 70–200 base pairs and large fragments of about 21 kilobases and it is 
longer than that of non neoplastic DNA [14]. 
Breast cancer 
Quantitative alterations of circulating DNA 
Some quantitative studies reported increased concentrations of circulating DNA in patients with breast 
cancer when compared to healthy individuals [15], [16] and [17]. Frattini et al. demonstrated that the levels 
of cf-DNA present in cancer patients constitute a stable parameter over the time and its variations may be 
correlated with clinical outcome [15]. Large individual variations in DNA quantity have been observed 
among different studies. A comprehensive review reported that the concentration of DNA in the 
bloodstream of patients with breast cancer (BC) varied from 153 to 549 ng/ml in serum and from 122 to 
462 ng/ml in plasma, whereas that of healthy controls ranged between 63–318 and 3–63 ng/ml, 
respectively [10]. 
A study by Kohler et al. showed significantly higher levels of cf-DNA in patients with BC in comparison to 
the patients with benign breast tumors and healthy individuals. This quantitative approach could 
distinguish between cancer patients and healthy controls with a sensitivity and specificity of 81% and 69%, 
respectively [16]. 
Catarino et al. quantified circulating DNA using real-time PCR (polymerase chain reaction) and showed that 
the cf-DNA levels were higher before breast surgery respect to post-operative time. This observation 
proved that cf-DNA may be a useful tool for monitoring disease. In addition, elevated levels of cf-DNA were 
found to be associated with tumor size, lymph node involvement, histopathological grade, and clinical 
staging[17]. These results were in accordance with previous observations in which the cf-DNA of BC 
patients also correlated with stage, lymph node metastasis and tumor size[4] and [18]. 
Qualitative alterations of circulating DNA 
Several studies reported that a qualitative analysis of specific molecular alterations in isolated DNA from 
tumoral tissue may mirror cf-DNA [19]. The presence of specific mutations helps to differentiate circulating 
tumor DNA (ct-DNA) from normal cf-DNA. These somatic mutations, commonly single base pair 
substitutions, are present only in the genomes of cancer cells or pre-cancerous cells and are never present 
in the DNA of normal cells of the same individual. This juxtaposition confers to ct-DNA elevated specificity 
as a biomarker. 
Four studies, for a total of 371 patients with breast cancer, analyzed the mutations of the tumor suppressor 
gene TP53 [20], [21], [22] and [23]. 
Great variations in incidence were described in the 4 different studies, ranging from 11% to 73% and 5% to 
43% for tumors and circulating DNA, respectively. These great variations should be considered as the 
consequence of the different methodologies used. 
Also the PIK3CA mutations were detected in the plasma in up to 30% of patients with advanced breast 
cancer [24], [25] and [26]. In the study of Board and colleagues [24], thePIK3CA mutations were detected in 
cf-DNA of 13/46 (28%) patients with metastatic breast cancer but were not detected in cf-DNA of patients 
with operable breast cancer. The concordance was 95% for PIK3CA mutations found in cf-DNA compared to 
those found in tumor DNA. These results clearly demonstrated that the detection of cf-DNA mutations is 
lower in the early stage disease compared to more advanced disease and demonstrated the feasibility of 
detection of PIK3CA mutation in cf-DNA. 
A more recent study showed how the analysis of ct-DNA can be integrate in the clinical management of BC 
patients [27]. 
Dawson et al. [27] compared the radiographic imaging of tumors with the assay of ct-DNA, CA 15.3 and 
circulating tumor cells in 30 patients with advanced breast cancer during chemotherapy administration. Ct-
DNA was identified in 29 of the 30 women (97%) in whom somatic genomic alterations 
of TP53 and PIKC3A were detected. This assay proved to have a higher sensitivity for detecting presence of 
metastatic disease when compared with assays of CA 15-3 or circulating tumor cells. Furthermore, the 
researchers found that measurement of levels of ct-DNA corresponds both with treatment response and 
survival: those who survived longer had lower levels of ct-DNA compared with those who survived a shorter 
period of time. These initial studies involved patients with high tumor burden and it remains to be 
evaluated if similar sensitivity can be achieved in patients with localized disease. 
Additional genetic alterations that are detectable on cf-DNA and are used as biomarkers in cancer include 
the integrity of non-coding genomic DNA repeat sequences such asALU and LINE1. 
The ALU and LINE1 sequences are involved in various physiological events such as DNA repair, transcription, 
epigenetic and transposon-based activity [28]and many studies showed their potential prognostic and 
diagnostic utility [29] and [30]. The assays are based on the observation that common DNA repeat 
sequences are preferentially released by tumor cells that are undergoing non apoptotic or necrotic cell 
death, and these fragments can be between 200 and 400 bp in size [12]. The integrity of cf-
DNA ALU sequences in blood has been shown to be sensitive for the assessment of the early stage of BC 
progression, including micrometastasis [30]. 
Also the microsatellite instability [MSI] and loss of heterozygosity [LOH] of cf-DNA were observed to have 
potential application in the management of patients with BC [6],[8] and [31]. 
A recent study [31] showed that the detection of DNA losses of the tumor suppressor 
genes TIG1, PTEN, cyclin D2, RB1, and BRCA1 on cf-DNA was associated with a more aggressive biology of 
BC. In particular, the detected cyclin D2 loss was an indicator of an unfavorable prognosis. Thus, the 
improved detection of cf-DNA might provide clinically relevant information on the variable biology of BC. In 
addition, LOH was not detected in the healthy subjects whereas it was observable in patients with 
carcinoma in situ [6]indicating the potential application of this analysis in the screening proceedings. 
Recently it has been observed that epigenetic changes are a constant alterations in cancer cells and they 
have a substantial effect on early carcinogenesis and progression[32]. The most examined epigenetic 
modification is that of DNA methylation. 
A small set of genes (APC, RASSF1A, DAP kinase) were found hypermethylated in the cf-DNA of patients 
with in situ carcinoma and with benign lesions [33], suggesting that this approach may be of particular 
interest in view of early molecular diagnosis. In addition it was seen that hypermethylation 
of RASSF1A and APC detected in serum DNA of BC patients was associated with a worse outcome [34]. It 
was seen, also, that the combined assessment of large amounts of free circulating total/methylated DNA 
and circulating tumor cells was predictive for tumor progression [35]. Other studies suggested that the 
assessment of abnormal methylation in the serum of BC patients may used for monitoring the efficacy of 
neoadjuvant [36] and adjuvant [37] and [38] treatment. Therefore, the detection of methylated cf-DNA 
represents a promising approach for risk assessment in cancer patients. 
Lung cancer 
Quantitative alterations of circulating DNA 
The quantitative analysis of cf-DNA as tool for the lung cancer monitoring was investigated in many studies. 
Significantly higher DNA concentrations were detected in the serum/plasma of lung cancer patients 
compared with healthy controls or patients with benign diseases [39] and [40]. 
In addition higher DNA levels have been reported in the serum of patients with metastatic disease than in 
patients with non metastatic disease, and it was seen that the cf-DNA levels decreased in 75% of the 
patients after therapy [3]. 
Sozzi et al. reported that the cf-DNA concentration was significantly lower in plasma of patients during the 
follow up than before surgery and was comparable to the concentration measured in the control group, 
suggesting that quantification of plasma DNA might represent a new approach to monitor surgical 
procedures or to assess the efficacy of chemo/radiotherapy [40]. 
Plasma DNA concentrations do not uniformly correlate with disease stage and histological subtypes [41]. 
Conflicting data exist regarding to the correlation of cf-DNA with survival. Some authors reported no 
correlation between plasma DNA concentrations and relapse-free or overall survival [40] and [41], whereas 
other authors reported an association of plasma DNA with survival, lactate dehydrogenase[39] and [42], 
and NSE [42] for a mixed group of SCLC and NSCLC patients [42], and for NSCLC patients only [39]. 
Qualitative alterations of circulating DNA 
Several oncogenes are involved in lung carcinogenesis, such as Ras, c-myc, tyrosine-kinase receptors (EGFR) 
and c-erbB2 (HER2/neu). 
Ramirez et al. reported K-ras mutations in 24% of 50 resected NSCLC patients [43] and Kimura et al. 
detected mutations in 20% of cases [44], whereas Bearzatto et al. did not find K-ras mutations in 
serum [45]. 
Camps et al. demonstrated that there were no significant differences between the NSCLC patients with K-
ras mutations in the serum and those with wild-type genotype with respect to baseline patient 
characteristics, response rates, progression-free survival, or overall survival [46]. Instead two other studies 
found an association between the presence of mutant K-ras in serum/plasma of NSCLC patients and 
survival[43] and [44]. In a more large study the plasma DNA of 180 lung patients was analyzed and it was 
found a significant correlation between the presence of K-ras mutations and poor prognosis [47]. 
The examination of EGFR mutations is essential to determine an appropriate lung cancer treatment 
strategy. Several clinical trials endorsed that the response rate to EGFR-TKI is approximately 70% in patients 
with EGFR activating/sensitive mutations, such as exon 19 deletions or L858R mutation [48]. 
Many studies have focused on detection of mutations in plasma or serum, to avoid the difficulty to obtain 
tumor specimens. 
Kimura et al. analyzed the EGFR mutation status in tumor and plasma of 42 patients treated with 
gefitinib. EGFR mutations were detected in the tumor samples of eight patients and in the serum samples 
of seven patients highlighting that EGFR mutation status in serum DNA was the same as in tumor samples 
in almost every patient. In addition, they demonstrated a correlation between the presence of 
the EGFR mutations in plasma DNA and the objective responses to gefitinib and as well as a trend towards 
increased overall survival in patients treated with gefitinib [49]. 
The EURTAC trial [50] reported, for patients with EGFR mutations detected in serum, an hazard ratio (HR) of 
0.25 in favor of erlotinib, which was similar to results from IPASS study (HR 0.29 in favor of gefitinib) [51]. 
Moreover, in the EURTAC trial, the subgroup analysis of EGFR mutations in cf-DNA showed that the 
presence of EGFR mutations was an independent prognostic marker for progression free survival (PFS) (HR 
0.43, 95% CI 0.26–0.73; p = 0.002). The PFS for patients with mutations detected in serum was 10.7 months 
(95% CI 6.8–15.5) in the erlotinib group compared with 4.2 months (3.2–6.0) in the standard chemotherapy 
group (HR 0.25, 95% CI 0.12–0.54; p = 0.0002). PFS for patients in whom mutations were not detected was 
12.6 months (95% CI 8.3−not assessable) in the erlotinib group compared with 6.0 months (4.9–9.0) in the 
standard chemotherapy group (HR 0.29, 95% CI 0.13–0.63; p = 0.0010) [50]. 
Another study demonstrated that the plasma levels of the mutant sequences of EGFRcorrelated with the 
clinical response and that a decreased concentration was detected in all patients with partial or complete 
clinical remission, whereas persistence of mutation was observed in the patient with cancer 
progression [52]. 
These studies suggest that the detection of EGFR and other mutations in cf-DNA could be used to 
monitoring response treatment and to detect the presence of new acquired mutations in plasma or serum. 
In 50% of lung cancer patients, acquired resistance to gefitinb or erlotinib, develops through the emergence 
of EGFR T790M variants [53]. The mutation at residue 790 increases the affinity of EGFR for ATP and so out-
competes binding of the inhibitors. These results have been initially obtained examining biopsies from 
patients who relapsed upon anti-EGFR and were later confirmed through the analyses of plasma, providing 
the first example that resistance to targeted therapies of solid tumors can be detected non-invasively in the 
blood of patients [54]. 
It was observed also that the MSI, the LOH and the epigenetic alterations of cf-DNA may have a potential 
application in the management of patients with lung cancer [40], [45],[55], [56] and [57]. 
Colorectal cancer 
Quantitative alterations of circulating DNA 
The detection of circulating DNA has strengthened its role as an additional tool for the management of 
patients with colorectal cancer (CRC). 
A study by Frattini et al. suggested that the quantification of plasma tumor DNA might be useful for 
monitoring patients with colorectal cancer and, prospectively, for recognizing high-risk individuals [58]. The 
data of this study showed that the plasma tumor DNA levels were significantly higher in patients with CRC, 
they decreased progressively in the follow up period in tumor-free patients and instead they increased in 
patients with recurrence or metastasis [58]. These results are in line with the findings of another study 
which demonstrated that serum DNA levels were significantly increased in stage IV CRC patients and they 
fluctuated during chemotherapy [59]. 
A study performed in a cohort of patients with CRC undergoing resection with curative intent showed that 
it is possible to define a unique set of molecular probes for each patient. These probes can then be 
exploited to quantify tumoral DNA after surgery. The patients were subsequently followed over the course 
of 2–5 years. In this study, ct-DNA was shown to be sufficiently sensitive to detect minimal residual disease 
after surgical resection [60]. 
Other studies reported higher levels of circulating DNA in CRC patients than in healthy individuals, but a 
correlation was not demonstrated between the levels of circulating DNA and the size and site of the tumor 
and the clinical course of disease [61] and [62]. 
Another study compared the sensitivity and specificity of cf-DNA with that of conventional serum marker 
carcinoembryonic antigen (CEA) and it was showed that cf-DNA, when used in combination with CEA, 
represents a potentially useful tool for the diagnosis of early stage CRC [63]. 
Qualitative alterations of circulating DNA 
Although anti-EGFR therapy has established efficacy in metastatic colorectal cancer (MCRC), only 10–20% 
of unselected patients respond [64]. This is partly due to KRASmutation, which is currently assessed in the 
primary tumor. Many studies assessed mutation status in circulating tumor DNA, with the aim to improve 
patient selection [65],[66], [67] and [68]. 
In the study published by Bazan et al., it was shown that the preoperative detection of 
mutant KRAS and TP53 in the serum of CRC patients undergoing resective surgery, was predictive of disease 
recurrence [65]. In another study it was detected the amount of circulating tumor DNA in 18 MCRC patients 
who underwent surgical resection of their metastases and it was observed that the detection of circulating 
mutant DNA after surgery was highly predictive of disease recurrence [66]. These results were agree with 
those of a previous study in which the probability to have a curative surgical resection has been shown to 
be lower in MCRC patients with measurable KRAS mutation in their serum [67]. 
Lefebure et al. detected, in the serum of unresectable MCRC, KRAS mutation andRASSF2A methylation and 
they observed that the presence of circulating mutant DNA was predictive of clinical outcome [68]. In a 
recent study was demonstrated the clinical utility of multiplex digital PCR to screen for multiple KRAS 
mutations in the plasma samples of MCRC patients [69] suggesting that the “liquid biopsy” is a feasible 
alternative to a solid tissue biopsy for identifying specific mutations. 
The principal limitations of therapies that target the extracellular domain of EGFR is the acquisition of 
secondary drug resistance. In a recent study was investigated whether the detection of KRAS mutant 
alleles, in the plasma of patients become refractory to anti-EGFR therapies, may allow the early 
identification of individuals at risk of develop drug resistance before radiographic documentation of disease 
progression [70]. 
It was found that KRAS mutant alleles were detectable in the blood of cetuximab treated patients as early 
as 10 months before the documentation of disease progression by radiologic assessment. Of relevance, the 
discovery of the mechanisms of resistance to the anti EGFR antibodies therapies in CRC was simultaneously 
accomplished in tissue and liquid biopsy. Another noteworthy aspect of this study was the emergence of 
multiple different resistance mutations in the same patient [70]. 
Overall these results indicate that the emergence of KRAS mutant clones can be detected months before 
radiographic progression and could allow an early initiation of combination therapies that may delay or 
prevent disease progression. 
DNA hypermethylation in serum of colorectal cancer patients has been reported to have prognostic and 
predictive value [61], [71], [72] and [73] and together with the assessment of DNA integrity [74] represents 
another promising tool for risk assessment. 
Prostate cancer 
Quantitative alterations of circulating DNA 
We need specific, sensitive and non invasive biomarkers for prostate cancer (PCA) diagnosis that could be 
used in addition to prostate-specific antigen (PSA) serial evaluations. The measurement of ct-DNA as a 
marker of tumor dynamics over conventional PSA or even imaging studies has been actively explored. 
Two studies failed to demonstrate significant differences of ct-DNA between patients with PCA and non 
malignant prostate disease [75] and [76]. In the first study [75] the failure could be due to the use of a less 
sensitive fluorometric assay, whereas other studies used a real time PCR and detected higher DNA levels in 
PCA patients than in non malignant prostate disease patients [77] and [78]. Cf-DNA levels were correlated 
with pathological stage [78], Gleason score, surgical margin status and extraprostatic extension [79]. In 
addition it was showed that cf-DNA increased with diagnosis of metastasis and was predictive of survival in 
patients with metastatic prostate cancer [75],[79] and [80]. 
Qualitative alterations of circulating DNA 
One of the earliest genetic alterations during prostate carcinogenesis seems to beGSTP1 CpG island 
hypermethylation. A recent meta-analysis of 22 manuscripts indicated good specificity (89%) but modest 
sensitivity (52%) of GSTP1 differential methylation for PCA screening [81]. The detection of 
hypermethylated DNA is also an adverse prognostic marker: RASSF1A, RARB2, and GSTP1 hypermethylation 
were correlated with the Gleason score and the serum PSA [82]. RARB2 and GSTP1methylation were also 
correlated with the AJCC stage [82]. GSTP1 hypermethylation was the strongest predictor of PSA recurrence 
following radical prostatectomy [83] and it was correlated with the Gleason score and the extent of 
metastasis in patients with hormone-refractory PCA [84]. 
Also the analysis of the fragmentation patterns of cf-DNA provide useful information in the management of 
prostate cancer. It was seen that the DNA integrity was higher in PCA patients than in controls [85]. Ellinger 
et al. demonstrated that the DNA integrity was a predictor of PSA recurrence following radical 
prostatectomy and that the DNA integrity may allow to recognize PCA patients and benign prostate 
hyperplasia patients with a specificity of 81% and a sensitivity of 68% [77]. 
Ovarian cancer 
Quantitative alterations of circulating DNA 
Ovarian cancer is the fifth leading cause of cancer death [86] in women. 
The cf-DNA has been investigated as novel biomarker for diagnosis, prediction and monitoring of 
therapeutic response in ovarian cancer. 
Kamat et al. showed that the levels of cf-DNA were elevated in patients with invasive epithelial ovarian 
cancer compare to the controls emphasizing the potential role of cf-DNA as an additional non invasive 
technique to identify women with malignant ovarian disease [87]. These findings were not consistent with 
a subsequent study showing that there was no statistical difference in the levels of cf-DNA between 
patients with ovarian cancer and patients with benign ovarian tumors [88]. One explanation for these 
results is the elevation of cf-DNA by other causes, including variation in the source, in fact cf-DNA in serum 
is reported to be higher than in plasma. 
In another study it was demonstrated also the utility of cf-DNA as surrogate biomarker of therapeutic 
response, using an orthotopic ovarian cancer model [89]. It was seen that cf-DNA correlated with tumor 
burden and the levels declined with chemotherapy. 
Kamat et al. investigated also the role of pre-operative total plasma cf-DNA levels in predicting clinical 
outcome in patients with ovarian cancer [90].The cf-DNA levels were significantly higher in patients with 
invasive cancer compared with women with benign ovarian tumors and controls and high cf-DNA levels 
correlated with aggressive phenotypic features such as high stage and high grade. In addition it was seen 
that cf-DNA >22,000 GE/ml was an independent predictor of poor outcome in patients with ovarian cancer, 
and was superior to CA 125 in predicting mortality [90]. Also another study reported a significant difference 
between the presence of cf-DNA in patients with high grade serous cancer compared with other 
histological subtypes [91]. 
Wimberger et al. observed a significant relationship between residual tumor load of >1 cm after primary 
surgery and serum DNA levels, and both parameters were associated with a higher risk of relapse and 
poorer overall survival [92]. 
Qualitative alterations of circulating DNA 
As the measurement of cf-DNA levels has some limitations as screening marker for ovarian cancer, in last 
years the research has focused on findings of specific alterations in cf-DNA, such as methylation or 
microsatellite alterations and mutation of tumor suppressor genes. 
In early detection of ovarian cancer, Liggett et al. found that methylation of RASSF1A andPGR-PROX in 
serum may be a useful biomarker to differentiate between benign and malignant ovarian tumors with a 
specificity of 73.3% and a sensitivity of 80.0% [93]. Another study showed that hypermethylation of at least 
one of six gene promoters, including RASSF1A, BRCA1, APC, DAPK and CDKN2A, was detected in the serum 
of early-stage ovarian cancer patients with 82% sensitivity; in contrast it was not reported 
hypermethylation in non neoplastic tissue, peritoneal fluid, or serum from 40 control women (100% 
specificity) [94]. Abnormal methylation of the HMLH1 promoter has been demonstrated to correlate with 
poor survival after chemotherapy [95] providing the possibility to identify those patients who relapse after 
standard chemotherapy and who would be suitable for novel epigenetic therapies. 
In a small study, tumor specific mutated p53 DNA levels were detected in the peritoneal fluid of 28 of 30 
(93%) women with intraperitoneal ovarian cancer, including all 6 cases with non malignant cells identified 
on cytopathology [96]. Therefore the identification of cf-DNA in peritoneal fluid compares favorably to 
cytopathologic evaluation, and warrants further investigation as a diagnostic marker. 
In ovarian cancer patients were investigated also the MSI and the DNA integrity with promising 
results [97] and [98]. 
Conclusion and perspectives 
The detection of cf-DNA provides new opportunities for management of cancer patients adding a new 
useful tool for diagnosis, staging and prognosis. It offers a new type of very specific biomarker that allow to 
identify the mutations accumulated from each tumor and to monitor the tumor burden and the response 
to treatment using a minimally invasive blood analyses (Table 1). 
Table 1. 
Detection of cf-DNA and its alterations in patients with solid tumors. 
Cf-DNA 
alterations 
Molecular alterations 
 
Breast Lung Colorectal Prostate Ovary 
Mutation TP53 (28–31,37) 
PIK3CA (32–34,37) 
RAS (63–
67) EGFR 
(72–77) 
RAS, TP53, APC 
(10,84,90,92–
94) 
– TP53 (127) 
DNA integrity Serum DNA 
integrity (40,41) 
– Serum DNA 
integrity (100) 
Serum DNA 
integrity 
(102,115) 
Serum DNA 
integrity (129) 
Microsatellite 
alterations 
LOH and MSI 
(9,11,42,43) 
LOH and 
MSI (8, 
78) 
– LOH and 
MSI 
(110,112) 
LOH (128) 
Methylation RASSF1A, APC, 
DAPK, ESR1, 
BRCA1, MGMT, 
GSTP1, Stratifin, 
MDR1, HSD17B4, 
HIC1, NEUROD1 
(48–53) 
P16 (65, 
79) 14-
3-
3sigma 
(80) 
SEPT9, ALX4, 
HLTF, HPP1 
(84, 95–99) 
GSTP1, 
RASSF1A, 
RARB2, AR 
(111–114) 
RASSF1A, PGR 
PROX, BRCA1, 
APC, DAPK, 
CDKN2A, 
HMLH1 (124, 
126) 
LOH, loss of heterozygosity; MSI, microsatellite instability. 
Table options 
In addition cf-DNA may have particular utility in the identification of mutations associated with acquired 
drug resistance in advanced cancers allowing to avoid repeat biopsies and to provide an evaluation of 
clonal genomic evolution associated with treatment response and resistance [70] and [99]. 
There are, however, several questions to be answered. One crucial factor in evaluating cf-DNA is the 
standardization of assays and the definition of the optimal sampling specimen (serum or plasma) to obtain 
data more consistent and comparative between different laboratories. Actually there are different 
procedures both in the pre-analytical phases (blood collection, processing, storage, baseline of patients), in 
DNA extraction, in quantification and analysis after the DNA extraction. These variables are critical and 
need to be standardized for consensus analysis and reporting. Despite these technical limitations, “liquid 
biopsy” may provide a unique opportunity in the field of clinical cancer research and have been already 
embedded in the design of several clinical trials (Table 2). Correlation of qualitative and quantitative 
analysis of circulating DNA with pathological response to neoadjuvant treatment in solid tumors may 
anticipate potential resistance to cytotoxic and biological agents during preoperative therapy. In the era of 
next generation sequencing detection of specific DNA mutations predicting response or resistance to 
targeted agents may anticipate switch to non cross-resistant therapies. The identification of circulating DNA 
in patients with breast cancer receiving neoadjuvant chemotherapy may predict pathological residual 
disease that correlate with poor prognosis in triple negative and HER2 positive breast cancer. Another 
opportunity to explore the role of cf-DNA is to study the “tumor dormancy” phenomenon. Analysis of cf-
DNA in patients in follow up for previous diagnosis of breast cancer has provided some hints regarding 
tumor dormancy. Specifically identification of cf-DNA might be employed to monitor patients with breast 
cancer without clinically detectable disease [100]comparing the genomic profiles of germline DNA, cf-DNA 
and tumor DNA as defined by single nucleotide polymorphism arrays. It is essential to highlight that plasma 
cf-DNA and primary tumor tissue showed some similarities regarding specific tumor copy-number 
variations as observed by DNA amplification at several chromosome arms [100]. The biological significance 
of cf-DNA in patients with no evidence of clinical disease is presently unclear; further studies are required 
to determine whether this approach is sufficiently sensitive as a screening tool or for identification of early 
relapse. More importantly, the process of identifying specific DNA mutations for each patient’s cancer is a 
laborious process that is currently too time-intensive and costly for more widespread use. Future 
development will have to provide a cost effective analysis mainly identifying the genes known to be 
recurrently mutated in each tumor. Therefore, developing standardized methodologies for cf-DNA analyses 
and validation in large prospective clinical studies is mandatory to implement the ‘liquid biopsy’ approach 
in the clinical management of cancer patients. 
Table 2. 
Ongoing clinical trials that study cf-DNA in solid tumors with therapeutic intervention. 
Clinical trial Status Therapeutic intervention Setting 
NCT00899548⁎  Recruiting Predict response after systemic therapy MBC 
NCT01198743⁎  Recruiting Validate prognostic value of cf-DNA Stage II–III CRC 
NCT00977457⁎  Recruiting Predict recurrence Prostate cancer 
undergoing surgery 
NCT01617915⁎  Recruiting Correlate cf-DNA with response to 
neoadjuvant CT 
BC candidate to 
neoadjuvant CT 
NCT01776684⁎  Recruiting Evaluation of EGFR TKI resistance 
mechanism 
NSCLC 
NCT01836640⁎  Not yet 
recruiting 
Evaluate cf-DNA as a surrogate for tumor 
biopsy to identify tumor genetic 
alterations 
MBC 
CT, chemotherapy; CRC, colorectal cancers; cf-DNA, circulating cell-free DNA; MBC, metastatic 
breast cancer; NSCLC, non small cell lung cancer; BC, breast cancer; EGFR TKI, epidermal growth 
factor receptor tyrosine kinase inhibitor. 
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